Pulmonx Corporation
- LUNG
- NASDAQ
- Medical devices
- Lung Volume Reduction (Zephyr Valve)
- COPD Treatment Devices
$1.75
Today −1.69%Quote Oct 19, 2026, 08:00 PM UTC
−10.10%over the last month
Max drawdown −15.0%From 1-month high −14.0%3 months +30.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Pulmonx
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema.
Sector
Healthcare
Industry
Medical devices
Exchange
NASDAQ
Employees
296
Founded
1995
Market value
$75.2M
Quote Oct 19
Floor
$1.75
0.2% below price
Resistance
$1.84
5.3% above price
Price vs analyst targets
9 analysts
Lowest target
$2.50Highest target
$20.00
$2.50Highest target
$20.00
- Price $1.75
- Average target $10.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 471% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LUNGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free